Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal

Daiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.